The first big fight over the Senate Finance Committee’s health care legislation erupted Tuesday night: a rollicking brawl over a deal that the Obama administration cut with the pharmaceutical industry to achieve $80 billion in savings on drug costs over 10 years, money that would help pay for the legislation.
Top House Democrats have hated the deal from the get-go. Senate Democrats are now bitterly divided. And Senate Republicans are eagerly jumping into the fray to needle the Democrats over their divisions.
Senator Bill Nelson, Democrat of Florida, has proposed an amendment that would essentially toss out the White House deal with PhRMA, the lobbying association for the drug industry. Mr. Nelson said his alternate plan would extract an additional $86 billion more from the drug industry.
One by one, the more liberal Democrats on the Finance panel, including John Kerry of Massachusetts, Charles E. Schumer of New York and Debbie Stabenow of Michigan, raced to Mr. Nelson’s side, asking to be added as co-sponsors of his amendment.
And Mr. Schumer, urging adoption of the amendment, warned that it would be an early litmus test for senators in the health care debate, by posing a clear choice of siding with average citizens or siding with a corporate interest group.
“This amendment is a metaphor in a certain sense for where this bill is headed,” Mr. Schumer said. A vote on the amendment is expected on Wednesday.
But as Democrats sharply criticized the deal with PhRMA as a giveaway to the drug industry, Senator Charles E. Grassley of Iowa, the senior Republican on the panel, interjected derisively. “You know who cut the deal,” he snapped at Mr. Schumer. Later, Mr. Grassley added: “If this is a bad deal, you ought to be embarrassed for your president. It didn’t come from anybody sitting on this side, this deal.”
Mr. Kerry tried to defend the Obama White House, suggesting that President Obama was not personally involved. But high-level White House officials, including a deputy chief of staff, participated in the negotiations.
And, as Mr. Grassley noted sarcastically, Mr. Obama has attended several news conferences with health industry groups, including the drug makers, to trumpet their support for his effort to overhaul the health system.
Senator Thomas R. Carper, Democrat of Delaware, warned that it would be unethical for Democrats to back away from the agreement with the drug industry, which was reached by top White House officials working closely with the Finance Committee chairman, Senator Max Baucus, Democrat of Montana.
“This is not the way that I would like to be treated,” Mr. Carper said. “Whether you like PhRMA or not, we have a deal.”
Mr. Schumer insisted that senators were not bound by the agreement. “That’s a value judgment,” he said. “This is going to be a constant debate when we come to this bill, and I don’t disagree that this is a difficult balance, but how often do we side with one of the interest groups, and how often do we side with the average citizens?”
The fight over the deal with PhRMA actually stems from the legislative battle over the Medicare prescription drug legislation that Republicans successfully pushed through Congress in 2003. As a result of that legislation, about 6 million elderly Americans who had been receiving drug benefits under Medicaid, the government insurance program for the poor, were instead shifted into the new Medicare drug program, resulting in the government paying far high prices for drugs.
Representative Henry Waxman, Democrat of California, and now the powerful chairman of the House Energy and Commerce Committee, has long complained about that switch. And the House health care legislation, of which Mr. Waxman is a main author, seeks to reverse the arrangement and to recoup the extra money that the government has been spending by restoring the old Medicaid drug discounts or “rebates” as they are known.
That would save the government at least $86 billion over 10 years, but would potentially cost the drug industry far more.
“You know who pays for that deal,” Mr. Kerry intoned. “The taxpayers. Taxpayers are paying for that. Taxpayers are covering the difference because PhRMA won’t.”
The White House has said that its deal with PhRMA would help narrow a gap in Medicare coverage of prescription drugs that is known as the doughnut hole, which forces people to pay some of their drug costs after a certain level. But also there are questions about the extent to which the drug industry also benefits, because the increased drug coverage for seniors means that the government will pay for more medication on their behalf, particularly brand-name drugs. In some cases, seniors now stop taking medication or switch to generics when they reach the doughnut hole.
Since the White House reached its deal with PhRMA in June there has been some disagreement between the industry and the administration over the precise terms of the arrangement. PhRMA has insisted that the White House agreed not to seek any additional concessions from drug manufacturers and to block Mr. Waxman’s plan in the House legislation. And the industry said that its support of the health overhaul was specifically aimed at Mr. Baucus’s proposal.
Mr. Baucus had previously announced that the first votes on amendments would not take place until Wednesday, so a final outcome of the fight was postponed.
Comments are no longer being accepted.